1. Market Research
  2. > Healthcare Market Trends

NPS+ Rheumatoid Arthritis (US)

  • September 2016
  • Firstword Pharma
Report ID: 3607566

Summary

Table of Contents




Satisfaction survey results: Top 2 brands are way ahead of the pack. Can your brand close the gap?
In the US rheumatoid arthritis (RA) treatment market, the two leading brands are trouncing the competition, earning far and away the highest satisfaction and loyalty scores. Can rivals catch up, or are they stuck jockeying for position in the mid-market?
Get the full story in FirstView NPS+ Rheumatoid Arthritis (US). Request sample pages
Based on a survey of 100 rheumatologists, the report builds on the respected net promoter score (NPS), comparing brand loyalty for 8 major RA treatments and highlighting ways you can improve your brand’s health—and boost market share—with easy-to-use KPIs.
Interested in the European market? Click here to see the EU5 Edition.





Top Takeaways


Two undisputed winners: While 7 of the 8 surveyed brands have a positive NPS, the two leading brands are way ahead of the pack. These same two brands dominate the EU5 market as well.
Brand loyalty is limited: Although more than three quarters of the rheumatologists surveyed are satisfied with available drugs, few promote one brand exclusively. Loyalty scores and recommendation patterns also highlight a willingness to switch brands.
“Passive” potential for middle-ranking brands: Most brands have high numbers of “Passives” who are more closely aligned with Promoters than Detractors. The report’s brand message associations may provide the key to winning them over.
One brand poised for a massive share gains: Comparatively low ranked, this brand stands to quintuple its market share if it can turn its Detractors into Promoters. No other brand comes close in terms of potential gain.
Clinical concerns are the top priorities: Safety, efficacy, and other clinical issues drive the most brand recommendations, and resonate with more doctors, than other concerns. The report reveals which specific messages are most effective for each surveyed brand.


Insight into 8 Major Rheumatoid Arthritis Drugs


Actemra (tocilizumab; Roche/Genentech)
Cimzia (certolizumab pegol; UCB)
Enbrel (etanercept; Amgen)
Humira (adalimumab; AbbVie)
Orencia (abatacept; BMS)
Remicade (infliximab; Janssen Biotech)
Rituxan (rituximab; Roche/Genentech/Biogen)
Simponi (golimumab; Janssen Biotech)


A Report Based on Expert Knowledge

We surveyed 100 US rheumatologists chosen from the largest community of validated physicians in the world. The same community that pharma market researchers trust for reliable, fast intelligence.
We conducted the survey between August 1st and 4th, 2016.

Explore Important Brand Loyalty Issues
NPS+ Rheumatoid Arthritis (US) explores key issues affecting brand loyalty for drug manufacturers. You’ll learn:

How satisfied the RA market is.
How loyal doctors are to your brand.
How many other brands your Promoters recommend.
Which other brands your Promoters and Detractors recommend.
How much market share your brand has among Promoters and Detractors.
How much market share you stand to gain by converting Detractors into Promoters.
Which messages Promoters, Passives and Detractors associate with your brand.
Your brand DNA: what doctors really think of your brand—in their own words.


What is Net Promoter® Score?
NPS is a customer loyalty metric developed by (and a registered trademark of) Fred Reichheld, Bain & Company, and Satmetrix. It was introduced by Reichheld in his 2003 Harvard Business Review article One Number You Need to Grow.

How does NPS work?


NPS measures overall brand satisfaction and loyalty by asking one simple question:
"How likely are you to recommend this brand to a colleague?"
Responses - given on a scale of 0 (not at all likely) to 10 (extremely likely)—are used to classify respondents into 3 categories:

Detractors are those who answer 0 – 6.
Passives are those who answer 7 – 8.
Promoters are those who answer 9 - 10.


How is NPS calculated?
The percentage of detractors - the percentage of promoters = NPS.
For example, 25% Promoters, 55% Passives and 20% Detractors give you an NPS of +5.
NPS can range from -100 (everybody is a Detractor) to +100 (everybody is a Promoter). The higher the score the healthier the brand.

What is FirstView NPS+?
NPS+ turns your Net Promoter Score into actionable information by answering key questions about brand loyalty.
Each NPS+ report examines doctors’ relationships with the brands used to treat a major disease area—measuring brand loyalty and showing you how it affects your market share. NPS+ also examines “brand DNA”, revealing in doctors’ own words what brands mean to them.
Instead of one simple metric, NPS+ gives you a detailed picture of brand health that highlights areas for improvement, and helps you see exactly what steps you need to take next.



MONEY BACK GUARANTEE!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.













Satisfaction survey results: Top 2 brands are way ahead of the pack. Can your brand close the gap?
In the US rheumatoid arthritis (RA) treatment market, the two leading brands are trouncing the competition, earning far and away the highest satisfaction and loyalty scores. Can rivals catch up, or are they stuck jockeying for position in the mid-market?
Get the full story in FirstView NPS+ Rheumatoid Arthritis (US). Request sample pages
Based on a survey of 100 rheumatologists, the report builds on the respected net promoter score (NPS), comparing brand loyalty for 8 major RA treatments and highlighting ways you can improve your brand’s health—and boost market share—with easy-to-use KPIs.
Interested in the European market? Click here to see the EU5 Edition.





Top Takeaways


Two undisputed winners: While 7 of the 8 surveyed brands have a positive NPS, the two leading brands are way ahead of the pack. These same two brands dominate the EU5 market as well.
Brand loyalty is limited: Although more than three quarters of the rheumatologists surveyed are satisfied with available drugs, few promote one brand exclusively. Loyalty scores and recommendation patterns also highlight a willingness to switch brands.
“Passive” potential for middle-ranking brands: Most brands have high numbers of “Passives” who are more closely aligned with Promoters than Detractors. The report’s brand message associations may provide the key to winning them over.
One brand poised for a massive share gains: Comparatively low ranked, this brand stands to quintuple its market share if it can turn its Detractors into Promoters. No other brand comes close in terms of potential gain.
Clinical concerns are the top priorities: Safety, efficacy, and other clinical issues drive the most brand recommendations, and resonate with more doctors, than other concerns. The report reveals which specific messages are most effective for each surveyed brand.


Insight into 8 Major Rheumatoid Arthritis Drugs


Actemra (tocilizumab; Roche/Genentech)
Cimzia (certolizumab pegol; UCB)
Enbrel (etanercept; Amgen)
Humira (adalimumab; AbbVie)
Orencia (abatacept; BMS)
Remicade (infliximab; Janssen Biotech)
Rituxan (rituximab; Roche/Genentech/Biogen)
Simponi (golimumab; Janssen Biotech)


A Report Based on Expert Knowledge

We surveyed 100 US rheumatologists chosen from the largest community of validated physicians in the world. The same community that pharma market researchers trust for reliable, fast intelligence.
We conducted the survey between August 1st and 4th, 2016.

Explore Important Brand Loyalty Issues
NPS+ Rheumatoid Arthritis (US) explores key issues affecting brand loyalty for drug manufacturers. You’ll learn:

How satisfied the RA market is.
How loyal doctors are to your brand.
How many other brands your Promoters recommend.
Which other brands your Promoters and Detractors recommend.
How much market share your brand has among Promoters and Detractors.
How much market share you stand to gain by converting Detractors into Promoters.
Which messages Promoters, Passives and Detractors associate with your brand.
Your brand DNA: what doctors really think of your brand—in their own words.


What is Net Promoter® Score?
NPS is a customer loyalty metric developed by (and a registered trademark of) Fred Reichheld, Bain & Company, and Satmetrix. It was introduced by Reichheld in his 2003 Harvard Business Review article One Number You Need to Grow.

How does NPS work?


NPS measures overall brand satisfaction and loyalty by asking one simple question:
"How likely are you to recommend this brand to a colleague?"
Responses - given on a scale of 0 (not at all likely) to 10 (extremely likely)—are used to classify respondents into 3 categories:

Detractors are those who answer 0 – 6.
Passives are those who answer 7 – 8.
Promoters are those who answer 9 - 10.


How is NPS calculated?
The percentage of detractors - the percentage of promoters = NPS.
For example, 25% Promoters, 55% Passives and 20% Detractors give you an NPS of +5.
NPS can range from -100 (everybody is a Detractor) to +100 (everybody is a Promoter). The higher the score the healthier the brand.

What is FirstView NPS+?
NPS+ turns your Net Promoter Score into actionable information by answering key questions about brand loyalty.
Each NPS+ report examines doctors’ relationships with the brands used to treat a major disease area—measuring brand loyalty and showing you how it affects your market share. NPS+ also examines “brand DNA”, revealing in doctors’ own words what brands mean to them.
Instead of one simple metric, NPS+ gives you a detailed picture of brand health that highlights areas for improvement, and helps you see exactly what steps you need to take next.



MONEY BACK GUARANTEE!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.



Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Infectious Disease Testing Market 2021: A 74-Country Analysis--Supplier Shares and Strategies, Test Volume and Sales Segment Forecasts, Technology and Instrumentation Review

  • $ 59500
  • Industry report
  • May 2017
  • by Venture Planning Group

This unique 68-country survey from VPGMarketResearch.com provides data and analysis not available from any other published source. The survey is designed to assist diagnostics industry executives, as well ...

Europe Infectious Disease Testing Market 2021: A 31-Country Analysis--Supplier Shares and Strategies, Test Volume and Sales Segment Forecasts, Technology and Instrumentation Review

  • $ 47500
  • Industry report
  • May 2017
  • by Venture Planning Group

This new report from VPGMarketResearch.com provides data and analysis not available from any other published source. The survey is designed to assist diagnostics industry executives, as well as companies ...

Hematology and Flow Cytometry Analyzers and Reagents Market 2021: A 74-Country Analysis--Supplier Shares and Strategies, Test Volume and Sales Segment Forecasts, Technology and Instrumentation Review

  • $ 47500
  • Industry report
  • May 2017
  • by Venture Planning Group

This 74-country survey from VPGMarketResearch.com provides granular data and analysis not available elsewhere. The survey is designed to help current suppliers and potential market entrants identify and ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.